Tempus AI (NASDAQ:TEM) Downgraded by William Blair to Market Perform

William Blair downgraded shares of Tempus AI (NASDAQ:TEM) from an outperform rating to a market perform rating in a report issued on Wednesday, MarketBeat Ratings reports.

Several other brokerages have also issued reports on TEM. Piper Sandler reiterated a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and lifted their target price for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Wolfe Research initiated coverage on shares of Tempus AI in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Guggenheim started coverage on shares of Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $56.00 price objective on shares of Tempus AI in a report on Tuesday, January 14th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $58.55.

Tempus AI Stock Up 3.7 %

Shares of NASDAQ:TEM opened at $73.88 on Wednesday. The business has a fifty day simple moving average of $45.21 and a 200 day simple moving average of $49.73. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. Tempus AI has a 1 year low of $22.89 and a 1 year high of $79.49.

Insider Activity

In related news, major shareholder Bradley A. Keywell sold 395,800 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the transaction, the insider now directly owns 16,164,449 shares in the company, valued at $694,263,084.55. This represents a 2.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Andrew Polovin sold 51,504 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the completion of the sale, the executive vice president now directly owns 246,085 shares of the company’s stock, valued at approximately $10,431,543.15. This trade represents a 17.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 2,229,449 shares of company stock valued at $102,293,124.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. ExodusPoint Capital Management LP acquired a new stake in shares of Tempus AI during the 4th quarter worth approximately $1,916,000. Massachusetts Financial Services Co. MA bought a new position in Tempus AI in the fourth quarter worth $10,148,000. StoneX Group Inc. acquired a new stake in Tempus AI during the fourth quarter worth $527,000. Franklin Resources Inc. increased its holdings in Tempus AI by 240.5% in the 4th quarter. Franklin Resources Inc. now owns 2,762,173 shares of the company’s stock valued at $93,251,000 after buying an additional 1,950,862 shares during the period. Finally, Alliancebernstein L.P. raised its stake in shares of Tempus AI by 40.3% in the 4th quarter. Alliancebernstein L.P. now owns 945,133 shares of the company’s stock valued at $31,908,000 after buying an additional 271,591 shares in the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.